Who
Rachel Humphrey
Director
Company insider
Files Form 4 as: Director, Pyxis Oncology; Chief Medical Officer, Black Diamond Therapeutics; Chief Medical Officer, CytomX Therapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $1.2M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 21 Jan 2016
- Last trade
- 24 Mar 2026
- Last filed
- 25 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 21 Apr 2025filed 25 Mar 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Sold | $14K13,896 at $1.03 | filing |
| 21 Apr 2025filed 25 Mar 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Sold | $14K13,896 at $1.03 | filing |
| 17 Apr 2025filed 25 Mar 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Sold | $194200 at $0.97 | filing |
| 17 Apr 2025filed 25 Mar 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Sold | $194200 at $0.97 | filing |
| 14 Apr 2025filed 25 Mar 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Sold | $1,3621,400 at $0.9727 | filing |
| 14 Apr 2025filed 25 Mar 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Sold | $1,3581,400 at $0.97 | filing |
| 31 Mar 2025filed 2 Apr 2025 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | $36K36,979 at $0.98 | filing |
| 26 Mar 2024filed 28 Mar 2024 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code A | —38,741 at $0.00 | filing |
| 24 Mar 2023filed 28 Mar 2023 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code A | —58,064 at $0.00 | filing |
| 11 Aug 2022filed 15 Aug 2022 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —236,220 at $0.00 | filing |
| 17 Feb 2021filed 19 Feb 2021 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 8 Sep 2020filed 10 Sep 2020 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 8 Sep 2020filed 10 Sep 2020 | BDTX Black Diamond TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 Jan 2019filed 29 Jan 2019 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Mar 2018filed 5 Mar 2018 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,160 at $0.00 | filing |
| 2 Mar 2018filed 5 Mar 2018 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Code M | $107K16,160 at $6.61 | filing |
| 2 Mar 2018filed 5 Mar 2018 | CTMX CytomX TherapeuticsBiotechnology | SEC FORM 4 Sold | $485K16,160 at $30.00 | filing |
| 28 Feb 2018filed 2 Mar 2018 | CTMX CytomX Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,840 at $0.00 | filing |
News
Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)PYXS · themarketsdaily.com · 8 Oct 2026Contrasting Inovio Pharmaceuticals (NASDAQ:INO) & Pyxis Oncology (NASDAQ:PYXS)PYXS · tickerreport.com · 6 Oct 2026
0 headlines in the last 90 days name Rachel Humphrey; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.